Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cord blood boost: new drug shows promise in High-Risk leukemia patients

NCT ID NCT04103879

First seen Apr 02, 2026 · Last updated May 18, 2026 · Updated 8 times

Summary

This study tested a new method to make cord blood transplants safer and more effective for 30 people with high-risk leukemia or myelodysplasia. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, helping the body recover faster. Early results suggest lower rates of severe side effects and good survival, but patients still need long-term monitoring and may require ongoing medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORD BLOOD TRANSPLANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Erasmus Medical Center

    Rotterdam, Gelderland, 3015, Netherlands

  • Fred Hutchinson / University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • University of Colorado School of Medicine. Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.